No evidence or no alternative? Taking responsibility for off-label prescribing

Internal Medicine Journal

Volumn 42, Issue 3, 2012, Pages 247-251

  Ghinea, N ^a   Lipworth, W ^a,b   Kerridge, I ^b,c   Day, R ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

Coagulant; Evidence; Factor VII; Off label; Prescribing; Promotion

Indexed keywords

NOVONORDISK; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ARTICLE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; INAPPROPRIATE PRESCRIBING; LAW SUIT; OFF LABEL DRUG USE; OFF LABEL PRESCRIBING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPONSIBILITY; SYSTEMATIC REVIEW (TOPIC);

ADVERTISING AS TOPIC; AUSTRALIA; DECISION MAKING; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; FACTOR VIIA; HEMORRHAGE; HEMOSTATICS; HUMANS; MARKETING; OFF-LABEL USE; PATIENT PARTICIPATION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTION FEES; RECOMBINANT PROTEINS; SOCIAL RESPONSIBILITY;

EID: 84858724616     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02713.x     Document Type: Article

References (39)

1. Gazarian M, Kelly M, McPhee J, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006; 185: 554-48.
2. Bright JL. Positive outcomes through the appropriate use of off-label prescribing. Arch Intern Med 2006; 166: 2554-5.
3. Largent EA, Miller FG, Pearson SD. Going off label without venturing off course: evidence and ethical off-label prescribing. Arch Intern Med 2009; 169: 1745-7.
4. Spielmans GI. The promotion of olanzapine in primary care: an examination of internal industry documents. Soc Sci Med 2009; 69: 14-20.
5. Ratner M, Gura T. Off label or off limits? Nat Biotechnol 2008; 26: 867-75.
6. Dresser R, Frader J. Off label prescribing a call for heightened professional and government oversight. J Law Med Ethics 2009; 37: 476-86.
7. Rosoff PM, Coleman DL. The case for legal regulation of physicians' off-label prescribing. Notre Dame Law Rev 2011; 86: 649-92.
8. Radley DC, Finkelstein SN, Stafford RS. Off label prescribing among office-based physicians. Arch Intern Med 2006; 1066: 1021-6.
9. Mellor JD, Bensted KE, Chan PL. Off label and unlicensed prescribing in a specialist oncology center in Australia. Asia-Pac J Clin Onco 2009; 5: 242-6.
10. Kamble P, Sherer J, Chen H, Aparasu R. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv 2010; 61: 130-36.
11. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. The Lancet 2000; 356: 1735-6.
12. O'Reilly J, Dalal A. Off label or out of bounds? Prescriber and Marketer Liability for Unapproved Uses of FDA-approved drugs. Ann Health Law 2003; 12: 295-324.
13. Bazzano ATF, Mangione-Smith R, Schonalau M, Suttorp MJ, Brook RH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr 2009; 9: 81-8.
14. Chen DT, Wynia MK, Moloney RM, Alexander GC. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf 2009; 18: 1094-100.
15. Kalina M, Tinkoff G, Fulda G. Massive postpartum hemorrhage: recombinant factor VIIa use is safe but not effective. Del Med J 2011; 83: 109-13.
16. DeLoughery E, Lenfesty B, DeLoughery T. A retrospective case control study of recombinant factor VIIa in patients with intracranial haemorrhage caused by trauma. Br J Haematol 2011; 152: 667-9.
17. Chapman AJ, Blount AL, Davis AT, Hooker RL. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardiothorac Surg 2011; 40: 1314-19.
18. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth K etal. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-5.
19. Dutton R, Parr M, Tortella B, Champion H, Bernard G, Boffard K etal. Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma 2011; 71: 12-19.
20. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011; 154: 516-22.
21. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
22. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002; 49: S15-20.
23. Hendriks HGD, Van der Maaten JMAA, De Wolf J, Waterbolk TW, Slooff MJH, Van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001; 93: 287-9.
24. Moscardo F, Perez F, De La Rubia J, Balerdi B, Aznar I, Carceller S etal. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001; 114: 174-6.
25. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-90.
26. NSW Therapeutic Advisory Group. Recombinant factor VIIa in nonhaemophiliac conditions. Position statement 2007; [cited 2011 Sep 24]. Available from URL:.
27. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-800.
28. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN etal. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127-37.
29. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Elsenhut R etal. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154: 529-40.
30. Hsia C, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008; 248: 61-8.
31. Willis CD, Cameron PA, Phillips L. Variation in the use of recombinant activated factor VII in critical bleeding. Intern Med J 2010; 40: 486-93.
32. Avorn J, Kesselheim A. A hemorrhage of off-label use. Ann Intern Med 2011; 154: 566-7.
33. Karkouti K, Levy JH. A heamorhage of off-label use. Ann Intern Med 2011; 155: 339.
34. Hayanga AJ, Kaiser HE. Trends in the use of factor VII in cardiac surgery. Ann Intern Med 2011; 154: 516-22.
35. Medicines Australia. Medicines Australia Code of Conduct: breaches. Aust Prescr 2004; 27: 141.
36. Bray C. Novo Nordisk to Settle Marketing Suit. Wall Street Journal (Online) 10 June 2011. [cited 2011 Sep 24]. Available from URL:.
37. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N etal. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med 2010; 7: e1000352.
38. Riley JB, Basilius PA. Physicians' liability for off-label prescriptions. Nephrol News Issues 2007; 21: 43-4, 46-7.
39. Edlin R, Round J, Hulme C, McCabe C. Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br J Clin Pharmacol 2010; 70: 350-55.